Sam­sung Bi­o­log­ics and No­var­tis ink man­u­fac­tur­ing con­tract worth $81M

As Sam­sung Bi­o­log­ics, the biotech di­vi­sion of the Sam­sung Group, places more em­pha­sis on man­u­fac­tur­ing, the com­pa­ny is ink­ing a ma­jor new con­tract with No­var­tis.

The deal is worth $81 mil­lion, ac­cord­ing to a reg­u­la­to­ry fil­ing — though the com­pa­nies are keep­ing most of the de­tails un­der wraps for now. The fil­ing al­so dis­closed that the con­tract amount rep­re­sents about 6.4% of Sam­sung’s sales in the lat­est fis­cal year, which were list­ed at KRW 1.57 tril­lion, or $1.2 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER